CervoMed presents neflamapimod MRI data

CervoMed (CRVO) presented placebo-controlled magnetic resonance imaging analyses providing evidence that neflamapimod may increase the size and enhance the function of the basal forebrain in patients with dementia with Lewy bodies, or DLB. The findings from further analysis of the RewinD-LB Phase 2b clinical trial showed that right basal forebrain volume increased by 3.5% with neflamapimod treatment and decreased by 4.2% with placebo. CervoMed plans to initiate a Phase 3 trial in the second half of 2026. “Atrophy in the basal forebrain is an important driver of clinical symptoms and progression of DLB. Combined with our previously reported data in neflamapimod treated-patients with early AD, where we saw very similar effects on the basal forebrain, these MRI analyses provide strong evidence that neflamapimod is acting on the underlying cause of DLB by reducing basal forebrain atrophy, reinforcing our clinical and biomarker data and enhancing our belief that neflamapimod has the potential to make a meaningful difference for patients with DLB,” said John Alam, CEO of CervoMed.